PIL seeks sale of vaccines by SII, Bharat Biotech at ₹ 150
The Hindu
“Price control by the government is a must and such kind of loot and blackmail should not be permitted.”
A public interest litigation (PIL) has been filed in the Bombay High Court challenging the different rates for COVID-19 vaccines for the Centre and state governments and requesting direction to the Serum Institute of India (SSI) and Bharat Biotech to sell their vaccines at a uniform rate of Rs 150 per dose. The PIL, filed on April 24 by advocate Fayzan Khan and three law students, said the vaccine is presumed to be an essential commodity and hence its management and distribution cannot be left in the hands of private companies. "These pharma giants are milking the fear psychosis of the increased death rates due to COVID-19," it said.More Related News